Company / Cost of Revenue
Catalyst Pharmaceuticals Partners, Inc. Cost of Revenue History
FY2019-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cost of Revenue
$87.3M
FY2025
5-year range
$21.9M / $87.3M
FY2021-FY2025
Trend
+26.7%
vs FY2024
Sector context
#45 of 85
Health Care
What the data says
At $87M, Catalyst Pharmaceuticals Partners, Inc.'s cost of revenue ranks #41 of 85 in the Health Care sector. Cost of Revenue has increased for 6 consecutive years, from $15M in FY2019 to $87M in FY2025.
Based on SEC 10-K filings.
$87M in FY2025 with a 5-year CAGR of +38.6%.
Increased from $52M to $87M over the past 2 years.
Health Care sector context is included.
Cost of Revenue over time
Growth rates
- 3-Year CAGR
- +36.4%
- 5-Year CAGR
- +38.6%
- 10-Year CAGR
- -
Sector benchmark
#41 of 85 in Health CareTop 47% of 85This company $87.3M Sector average $2.0B
▼
-95.6% below sector average
Key checks
Key Insights
- Catalyst Pharmaceuticals Partners, Inc.'s cost of revenue has grown for 6 consecutive years.
- 5-year CAGR of +38.6%, indicating consistent growth.
- In FY2025, cost of revenue increased 26.7% year-over-year.
- Ranks #45 out of 85 companies in the Health Care sector.
Company context
Key Data Points
- Altman Z-Score 4.78 (safe zone, above 2.9 threshold)
- Strong profit margin: 33.3%
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cost of RevenueValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $87.3M | +26.7% |
| FY2024 | $68.8M | +32.5% |
| FY2023 | $52.0M | +51.1% |
| FY2022 | $34.4M | +57.2% |
| FY2021 | $21.9M | +28.4% |
| FY2020 | $17.0M | +15.4% |
| FY2019 | $14.8M | - |
| FY2018 | - | - |
| FY2017 | - | - |
| FY2016 | - | - |
As of FY2025 · SEC 10-K · Updated Jul 2, 2026